Could Araucaria heterophylla resin extract be used as a new treatment for toxoplasmosis?

Nora L. El-Tantawy, Amal F. Soliman, Aida Abdel-Magied, Doaa Ghorab, Ashraf T. Khalil, Zein M. Naeem, Kuniyoshi Shimizu, Saleh H. El-Sharkawy

研究成果: ジャーナルへの寄稿記事

抄録

Toxoplasmosis is a worldwide parasitic disease responsible for serious health problems to human. The currently available drugs used for toxoplasmosis treatment showed a limited efficacy and cause serious host toxicity. The in vitro screening for toxoplasmicidal activity of Araucaria heterophylla resin (AHR) extract and its major component 13-epi-cupressic acid (CUP) showed that both AHR (EC50 = 3.90) and CUP (EC50 = 3.69) have high toxoplasmicidal activity in comparison with standard cotrimoxazole (EC50 = 4.28). The antiprotozoal effects of AHR and CUP were investigated against acute and chronic toxoplasmosis using mice models. Two groups of Swiss albino mice were infected by RH Toxoplasma strain intraperitoneally and by Me49 strain orally. Both groups were treated with AHR and CUP in different doses. Their effects were evaluated by survival rate, peritoneal, spleen and liver parasite burdens, brain cyst burden, NO serum level and histopathological lesions. The ultrastructural changes of tachyzoites of acutely infected mice were studied using scanning electron microscopy (SEM). There is an evidence of toxoplasmicidal activity of AHR and CUP in acute and chronic experimental toxoplasmosis. In the acute model, mice treated with AHR and CUP showed prolonged survival rates, a significant decrease in the parasite density in peritoneal lavage and pathological insult in both liver and spleen compared with that of untreated ones. SEM results denote evident morphological alterations of treated tachyzoites. In chronic experimental toxoplasmosis, AHR and CUP treated groups could significantly reduce brain cyst burden by 96.05% and 98.02% respectively. This study indicates that AHR and CUP showed potent toxoplasmicidal activities experimentally and could be used as a potential natural nontoxic agent for treatment of toxoplasmosis.

元の言語英語
ページ(範囲)44-53
ページ数10
ジャーナルExperimental Parasitology
195
DOI
出版物ステータス出版済み - 12 1 2018

Fingerprint

Toxoplasmosis
Electron Scanning Microscopy
Cysts
Parasites
Therapeutics
Spleen
Peritoneal Lavage
Parasitic Diseases
Liver
Sulfamethoxazole Drug Combination Trimethoprim
Toxoplasma
Brain
Health
Serum
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Parasitology
  • Immunology
  • Infectious Diseases

これを引用

El-Tantawy, N. L., Soliman, A. F., Abdel-Magied, A., Ghorab, D., Khalil, A. T., Naeem, Z. M., ... El-Sharkawy, S. H. (2018). Could Araucaria heterophylla resin extract be used as a new treatment for toxoplasmosis? Experimental Parasitology, 195, 44-53. https://doi.org/10.1016/j.exppara.2018.10.003

Could Araucaria heterophylla resin extract be used as a new treatment for toxoplasmosis? / El-Tantawy, Nora L.; Soliman, Amal F.; Abdel-Magied, Aida; Ghorab, Doaa; Khalil, Ashraf T.; Naeem, Zein M.; Shimizu, Kuniyoshi; El-Sharkawy, Saleh H.

:: Experimental Parasitology, 巻 195, 01.12.2018, p. 44-53.

研究成果: ジャーナルへの寄稿記事

El-Tantawy, NL, Soliman, AF, Abdel-Magied, A, Ghorab, D, Khalil, AT, Naeem, ZM, Shimizu, K & El-Sharkawy, SH 2018, 'Could Araucaria heterophylla resin extract be used as a new treatment for toxoplasmosis?', Experimental Parasitology, 巻. 195, pp. 44-53. https://doi.org/10.1016/j.exppara.2018.10.003
El-Tantawy NL, Soliman AF, Abdel-Magied A, Ghorab D, Khalil AT, Naeem ZM その他. Could Araucaria heterophylla resin extract be used as a new treatment for toxoplasmosis? Experimental Parasitology. 2018 12 1;195:44-53. https://doi.org/10.1016/j.exppara.2018.10.003
El-Tantawy, Nora L. ; Soliman, Amal F. ; Abdel-Magied, Aida ; Ghorab, Doaa ; Khalil, Ashraf T. ; Naeem, Zein M. ; Shimizu, Kuniyoshi ; El-Sharkawy, Saleh H. / Could Araucaria heterophylla resin extract be used as a new treatment for toxoplasmosis?. :: Experimental Parasitology. 2018 ; 巻 195. pp. 44-53.
@article{d8cca14cf34844e4bd79ec33ea8998db,
title = "Could Araucaria heterophylla resin extract be used as a new treatment for toxoplasmosis?",
abstract = "Toxoplasmosis is a worldwide parasitic disease responsible for serious health problems to human. The currently available drugs used for toxoplasmosis treatment showed a limited efficacy and cause serious host toxicity. The in vitro screening for toxoplasmicidal activity of Araucaria heterophylla resin (AHR) extract and its major component 13-epi-cupressic acid (CUP) showed that both AHR (EC50 = 3.90) and CUP (EC50 = 3.69) have high toxoplasmicidal activity in comparison with standard cotrimoxazole (EC50 = 4.28). The antiprotozoal effects of AHR and CUP were investigated against acute and chronic toxoplasmosis using mice models. Two groups of Swiss albino mice were infected by RH Toxoplasma strain intraperitoneally and by Me49 strain orally. Both groups were treated with AHR and CUP in different doses. Their effects were evaluated by survival rate, peritoneal, spleen and liver parasite burdens, brain cyst burden, NO serum level and histopathological lesions. The ultrastructural changes of tachyzoites of acutely infected mice were studied using scanning electron microscopy (SEM). There is an evidence of toxoplasmicidal activity of AHR and CUP in acute and chronic experimental toxoplasmosis. In the acute model, mice treated with AHR and CUP showed prolonged survival rates, a significant decrease in the parasite density in peritoneal lavage and pathological insult in both liver and spleen compared with that of untreated ones. SEM results denote evident morphological alterations of treated tachyzoites. In chronic experimental toxoplasmosis, AHR and CUP treated groups could significantly reduce brain cyst burden by 96.05{\%} and 98.02{\%} respectively. This study indicates that AHR and CUP showed potent toxoplasmicidal activities experimentally and could be used as a potential natural nontoxic agent for treatment of toxoplasmosis.",
author = "El-Tantawy, {Nora L.} and Soliman, {Amal F.} and Aida Abdel-Magied and Doaa Ghorab and Khalil, {Ashraf T.} and Naeem, {Zein M.} and Kuniyoshi Shimizu and El-Sharkawy, {Saleh H.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.exppara.2018.10.003",
language = "English",
volume = "195",
pages = "44--53",
journal = "Experimental Parasitology",
issn = "0014-4894",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Could Araucaria heterophylla resin extract be used as a new treatment for toxoplasmosis?

AU - El-Tantawy, Nora L.

AU - Soliman, Amal F.

AU - Abdel-Magied, Aida

AU - Ghorab, Doaa

AU - Khalil, Ashraf T.

AU - Naeem, Zein M.

AU - Shimizu, Kuniyoshi

AU - El-Sharkawy, Saleh H.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Toxoplasmosis is a worldwide parasitic disease responsible for serious health problems to human. The currently available drugs used for toxoplasmosis treatment showed a limited efficacy and cause serious host toxicity. The in vitro screening for toxoplasmicidal activity of Araucaria heterophylla resin (AHR) extract and its major component 13-epi-cupressic acid (CUP) showed that both AHR (EC50 = 3.90) and CUP (EC50 = 3.69) have high toxoplasmicidal activity in comparison with standard cotrimoxazole (EC50 = 4.28). The antiprotozoal effects of AHR and CUP were investigated against acute and chronic toxoplasmosis using mice models. Two groups of Swiss albino mice were infected by RH Toxoplasma strain intraperitoneally and by Me49 strain orally. Both groups were treated with AHR and CUP in different doses. Their effects were evaluated by survival rate, peritoneal, spleen and liver parasite burdens, brain cyst burden, NO serum level and histopathological lesions. The ultrastructural changes of tachyzoites of acutely infected mice were studied using scanning electron microscopy (SEM). There is an evidence of toxoplasmicidal activity of AHR and CUP in acute and chronic experimental toxoplasmosis. In the acute model, mice treated with AHR and CUP showed prolonged survival rates, a significant decrease in the parasite density in peritoneal lavage and pathological insult in both liver and spleen compared with that of untreated ones. SEM results denote evident morphological alterations of treated tachyzoites. In chronic experimental toxoplasmosis, AHR and CUP treated groups could significantly reduce brain cyst burden by 96.05% and 98.02% respectively. This study indicates that AHR and CUP showed potent toxoplasmicidal activities experimentally and could be used as a potential natural nontoxic agent for treatment of toxoplasmosis.

AB - Toxoplasmosis is a worldwide parasitic disease responsible for serious health problems to human. The currently available drugs used for toxoplasmosis treatment showed a limited efficacy and cause serious host toxicity. The in vitro screening for toxoplasmicidal activity of Araucaria heterophylla resin (AHR) extract and its major component 13-epi-cupressic acid (CUP) showed that both AHR (EC50 = 3.90) and CUP (EC50 = 3.69) have high toxoplasmicidal activity in comparison with standard cotrimoxazole (EC50 = 4.28). The antiprotozoal effects of AHR and CUP were investigated against acute and chronic toxoplasmosis using mice models. Two groups of Swiss albino mice were infected by RH Toxoplasma strain intraperitoneally and by Me49 strain orally. Both groups were treated with AHR and CUP in different doses. Their effects were evaluated by survival rate, peritoneal, spleen and liver parasite burdens, brain cyst burden, NO serum level and histopathological lesions. The ultrastructural changes of tachyzoites of acutely infected mice were studied using scanning electron microscopy (SEM). There is an evidence of toxoplasmicidal activity of AHR and CUP in acute and chronic experimental toxoplasmosis. In the acute model, mice treated with AHR and CUP showed prolonged survival rates, a significant decrease in the parasite density in peritoneal lavage and pathological insult in both liver and spleen compared with that of untreated ones. SEM results denote evident morphological alterations of treated tachyzoites. In chronic experimental toxoplasmosis, AHR and CUP treated groups could significantly reduce brain cyst burden by 96.05% and 98.02% respectively. This study indicates that AHR and CUP showed potent toxoplasmicidal activities experimentally and could be used as a potential natural nontoxic agent for treatment of toxoplasmosis.

UR - http://www.scopus.com/inward/record.url?scp=85056652442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056652442&partnerID=8YFLogxK

U2 - 10.1016/j.exppara.2018.10.003

DO - 10.1016/j.exppara.2018.10.003

M3 - Article

C2 - 30339984

AN - SCOPUS:85056652442

VL - 195

SP - 44

EP - 53

JO - Experimental Parasitology

JF - Experimental Parasitology

SN - 0014-4894

ER -